JPMorgan Chase & Co. Upgrades Replimune Group (NASDAQ:REPL) to "Neutral"

Key Points

• JPMorgan Chase & Co. upgraded Replimune Group from an "underweight" rating to a "neutral" rating, reflecting a shift in analysts' sentiment.
• Replimune Group’s stock had a significant price increase, trading up $4.47 to reach $8.97 during recent trading sessions.
• The stock's average rating is currently "Hold" with an average price target of $9.50, indicating a mixed outlook from analysts.

Replimune Group (NASDAQ:REPL - Get Free Report) was upgraded by investment analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating in a report released on Monday,Briefing.com Automated Import reports.

Other research analysts have also recently issued research reports about the company. BMO Capital Markets cut Replimune Group from an "outperform" rating to an "underperform" rating and decreased their price target for the stock from $27.00 to $2.00 in a research note on Wednesday, July 23rd. HC Wainwright restated a "neutral" rating on shares of Replimune Group in a research report on Monday, September 8th. Jefferies Financial Group lowered their price objective on shares of Replimune Group from $31.00 to $6.00 and set a "buy" rating on the stock in a research note on Tuesday, July 22nd. Leerink Partners upgraded Replimune Group from a "market perform" rating to an "outperform" rating and upped their target price for the stock from $3.00 to $13.00 in a research report on Monday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Replimune Group in a research report on Tuesday, October 14th. Four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $9.50.

Replimune Group Stock Performance

Shares of REPL stock traded up $4.47 during trading hours on Monday, reaching $8.97. The stock had a trading volume of 103,257,365 shares, compared to its average volume of 4,485,184. The firm has a market capitalization of $700.43 million, a PE ratio of -2.77 and a beta of 0.42. The firm has a 50-day simple moving average of $5.03 and a 200-day simple moving average of $7.27. Replimune Group has a twelve month low of $2.68 and a twelve month high of $17.00. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.94 and a quick ratio of 6.94.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.83) by ($0.12). As a group, equities analysts forecast that Replimune Group will post -2.97 earnings per share for the current year.

Insider Activity at Replimune Group

In other Replimune Group news, CFO Emily Luisa Hill sold 9,154 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $5.37, for a total transaction of $49,156.98. Following the sale, the chief financial officer owned 134,368 shares in the company, valued at approximately $721,556.16. The trade was a 6.38% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 5.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in REPL. US Bancorp DE lifted its holdings in shares of Replimune Group by 582.6% in the first quarter. US Bancorp DE now owns 4,594 shares of the company's stock valued at $45,000 after purchasing an additional 3,921 shares in the last quarter. BNP Paribas Financial Markets raised its position in Replimune Group by 37.5% during the second quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company's stock valued at $64,000 after buying an additional 1,879 shares during the period. Raymond James Financial Inc. purchased a new stake in Replimune Group in the 2nd quarter worth about $69,000. Griffin Asset Management Inc. acquired a new stake in Replimune Group during the 3rd quarter worth about $82,000. Finally, Tower Research Capital LLC TRC grew its stake in Replimune Group by 2,020.8% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,692 shares of the company's stock valued at $90,000 after acquiring an additional 9,235 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.